Van K. Morris

The University of Texas MD Anderson Cancer Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination

(2023)10.1158/2767-9764.c.6975005.v1

Top 100%

0DataRank

Top 100%0 citations

Jane V. Thomas, Kaysia Ludford, Jason Willis, Victoria Serpas Higbie, Kanwal Raghav +15 more

Papers

Driven by 45 papers — median percentile 0. Top paper: “Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer”.

Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer

New England Journal of Medicine(2025)10.1056/nejmoa2501912

N/A

1.9DataRank · unranked

114 citations

Takayuki Yoshino, Lin Shen, Sara Lonardi, Eric Van Cutsem, Cathy Eng +15 more

Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2403

N/A

1.5DataRank · unranked

34 citations

Rajyalakshmi Luthra, Yusha Liu, Dzifa Y. Duose, Wonyul Lee, Neelima G. Reddy +20 more

A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAFV600E-MutantKRASWild-Type Metastatic Colorectal Cancer

The Oncologist(2023)10.1093/oncolo/oyad007

N/A

1.2DataRank · unranked

53 citations

Eric Van Cutsem, Elena Garralda, David Tai, Filippo de Braud, Ravit Geva +9 more

Software-based versus visual assessment of the minimal ablative margin in patients with liver tumours undergoing percutaneous thermal ablation (COVER-ALL): a randomised phase 2 trial

The Lancet. Gastroenterology & hepatology(2025)10.1016/s2468-1253(25)00024-x

N/A

1.0DataRank · unranked

51 citations

Jessica Albuquerque, Yuan‐Mao Lin, Brian Anderson, Caleb S O'Connor, B. Rigaud +25 more

First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-008668

N/A

0.742DataRank · unranked

29 citations

Tobias A.W. Holderried, Jason J. Luke, Van K. Morris, Winfried Alsdorf, Katrin Wetzko +27 more

Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer

Cancer Immunology Research(2023)10.1158/2326-6066.cir-22-0444

N/A

0.656DataRank · unranked

14 citations

Kerstin Guenther, Börje S. Andersson, Regina Mendrzyk, Amir Alpert, Claudia Wagner +36 more

Prognostic impact of lymphopenia and neutrophil-lymphocyte ratio for patients with anal squamous cell carcinoma

Journal of Gastrointestinal Oncology(2021)10.21037/jgo-21-323

N/A

0DataRank · unranked

14 citations

Ethan B. Ludmir, Craig Messick, Matthew Cagley, Van K. Morris, Prajnan Das +8 more

Phase II trial of bintrafusp alfa in patients with metastatic MSI-H cancers following progression on immunotherapy.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.79

N/A

0DataRank · unranked

15 citations

Michael Lam, Xuemei Wang, Michael J. Overman, Benny Johnson, Bryan K. Kee +7 more

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer:NRG-GI005 (COBRA).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.tps148

N/A

0DataRank · unranked

5 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +7 more

Phase II/III study of Circulating tumOr DNA as a predictive BiomaRker in Adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps3622

N/A

0DataRank · unranked

2 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +7 more

Epigenetic regulation of the Wnt-signaling pathway in CIMP-H BRAFV600E mCRC.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.110

N/A

0DataRank · unranked

0 citations

Stefania Napolitano, Van K. Morris, Kunal Rai, John Paul Shen, Jennifer S. Davis +8 more

Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6

Cancer Research(2022)10.1158/0008-5472.can-22-0198

N/A

0DataRank · unranked

81 citations

Preeti Kanikarla Marie, Lea Bitner, Muddassir Syed, Melanie Woods, Ganiraju C. Manyam +8 more

Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution

The Oncologist(2022)10.1093/oncolo/oyab006

N/A

0DataRank · unranked

21 citations

Van K. Morris, Benny Johnson, Cathy Eng, Ethan B. Ludmir, Prajnan Das +15 more

Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience

The Oncologist(2022)10.1093/oncolo/oyac162

N/A

0DataRank · unranked

21 citations

Jane E. Rogers, Hyunsoo Hwang, Wei Qiao, Lianchun Xiao, Arvind Dasari +11 more

Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer

Journal of Gastrointestinal Oncology(2022)10.21037/jgo-21-471

N/A

0DataRank · unranked

4 citations

Bryan K. Kee, Michael J. Overman, Arvind Dasari, Kanwal Raghav, Benny Johnson +6 more

Phase 2 study of anti-EGFR rechallenge therapy with panitumumab with or without trametinib in advanced colorectal cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3520

N/A

0DataRank · unranked

9 citations

Eduardo Vilar Sanchez, Ryan Sun, Madhulika Eluri, Van K. Morris, Benny Johnson +11 more

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.tps233

N/A

0DataRank · unranked

3 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +8 more

Encorafenib, cetuximab, and cytotoxic chemotherapy combinations in BRAFV600E CRC murine models.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.145

N/A

0DataRank · unranked

0 citations

Vincenzo De Falco, Claudia Prisco, Giulia Martini, Luigi Pio Guerrera, Valentina Belli +11 more

RAS co-mutation and early onset disease represent an aggressive phenotype of atypical (non-V600) BRAF mutant metastatic colorectal cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3592

N/A

0DataRank · unranked

0 citations

Dongyun Yang, Hiba I. Dada, Van K. Morris, Xuemei Wang, Arvind Dasari +14 more

Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination

Cancer Research Communications(2023)10.1158/2767-9764.crc-23-0340

N/A

0DataRank · unranked

15 citations

Jane V. Thomas, Kaysia Ludford, Jason Willis, Victoria Serpas Higbie, Kanwal Raghav +15 more

Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers

The Oncologist(2023)10.1093/oncolo/oyad085

N/A

0DataRank · unranked

28 citations

Amir A. Jazaeri, Shannon N. Westin, Curtis A. Pettaway, Solly George, Ryan Huey +8 more

HPV-related anal cancer is associated with changes in the anorectal microbiome during cancer development

Frontiers in Immunology(2023)10.3389/fimmu.2023.1051431

N/A

0DataRank · unranked

20 citations

Victoria O. Huynh, Daniel Lin, R. Tyler Hillman, Chike O. Abana, Molly B. El Alam +20 more

Prognostic and Predictive Markers for Patients With Anal Cancer

Journal of the National Comprehensive Cancer Network(2023)10.6004/jnccn.2023.7031

N/A

0DataRank · unranked

9 citations

Arjun Peddireddy, Van K. Morris, Emma B. Holliday

Differential Spatial Gene and Protein Expression Associated with Recurrence Following Chemoradiation for Localized Anal Squamous Cell Cancer

Cancers(2023)10.3390/cancers15061701

N/A

0DataRank · unranked

7 citations

Prajnan Das, Emma B. Holliday, Li Shen, Wei Lü, Benny Johnson +20 more

Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer: SWOG S2107.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps265

N/A

0DataRank · unranked

8 citations

Katherine A. Guthrie, Scott Kopetz, Rimini Breakstone, Thomas B. Karasic, Zishuo Ian Hu +6 more

P-228 Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer: SWOG S2107

Annals of Oncology(2023)10.1016/j.annonc.2023.04.284

N/A

0DataRank · unranked

2 citations

Katherine A. Guthrie, Scott Kopetz, Rimini Breakstone, Thomas B. Karasic, Zelan Hu +7 more

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps259

N/A

0DataRank · unranked

1 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +8 more

Data from Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6

(2023)10.1158/0008-5472.c.6513959.v1

N/A

0DataRank · unranked

0 citations

Preeti Kanikarla Marie, Lea Bitner, Muddassir Syed, Melanie Woods, Ganiraju C. Manyam +8 more

Supplementary Figure from Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6

(2023)10.1158/0008-5472.22431731

N/A

0DataRank · unranked

0 citations

Preeti Kanikarla Marie, Lea Bitner, Muddassir Syed, Melanie Woods, Ganiraju C. Manyam +8 more

Data from Bintrafusp Alfa, an Anti-PD-L1:TGFβ Trap Fusion Protein, in Patients with ctDNA-positive, Liver-limited Metastatic Colorectal Cancer

(2023)10.1158/2767-9764.c.6550830.v1

N/A

0DataRank · unranked

0 citations

Michael J. Overman, Michael Hon‐Wah Lam, Christine M. Parseghian, Benny Johnson, Arvind Dasari +17 more

Is there an increase in elective utilization of non-operative management for rectal cancer?

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e15533

N/A

0DataRank · unranked

0 citations

Chung‐Yuan Hu, Abhineet Uppal, Oliver Peacock, Brian K. Bednarski, Tsuyoshi Konishi +13 more

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps3625

N/A

0DataRank · unranked

0 citations

Greg Yothers, Scott Kopetz, Shannon L. Puhalla, Peter C. Lucas, Atif Iqbal +8 more

584 Phase I/II study to evaluate the safety and tolerability of avelumab in combination with other anti-cancer therapies in patients with advanced malignancies

Regular and Young Investigator Award Abstracts(2023)10.1136/jitc-2023-sitc2023.0584

N/A

0DataRank · unranked

0 citations

Anne Knisely, Bettzy Stephen, Yali Yang, Juhee Song, Anas Alshawa +9 more

Data from Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination

(2023)10.1158/2767-9764.c.6975005.v1

Top 100%

0DataRank

Top 100%0 citations

Jane V. Thomas, Kaysia Ludford, Jason Willis, Victoria Serpas Higbie, Kanwal Raghav +15 more

Epigenome Reprogramming Through H3K27 and H3K4 Trimethylation as a Resistance Mechanism to DNA Methylation Inhibition in BRAFV600E-Mutated Colorectal Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1166

N/A

0DataRank · unranked

19 citations

Ajay Kumar Saw, Van K. Morris, Stefania Napolitano, Christopher A. Bristow, Sanjana Srinivasan +11 more

Mutational and co-mutational landscape of early onset colorectal cancer

Biomarkers(2025)10.1080/1354750x.2024.2447089

N/A

0DataRank · unranked

24 citations

Guglielmo Vetere, Giulia Maddalena, Mahmoud Yousef, Michael G. White, John Paul Shen +14 more

Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer

Cancer Cell(2025)10.1016/j.ccell.2025.08.002

N/A

0DataRank · unranked

22 citations

Christine M. Parseghian, Vahid Bahrambeigi, Nourhan Abdelfattah, Lianchun Xiao, Anjali Agrawal +28 more

Time Dependency for Human Papillomavirus Circulating Tumor DNA Detection after Chemoradiation as a Prognostic Biomarker for Localized Anal Cancer

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-2575

N/A

0DataRank · unranked

9 citations

Weihong Xiao, Kangyu Lin, Chi Wut Wong, Michael Wotman, Emma B. Holliday +16 more

Population-based Screening for BRAF V600E in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-1024

N/A

0DataRank · unranked

43 citations

Benny Johnson, Laveniya Kugathasan, Van K. Morris, Kanwal Raghav, Lucas Swanson +9 more

Advances in anal cancer treatment: current standards, the role of immunotherapy and emerging strategies

ESMO Gastrointestinal Oncology(2025)10.1016/j.esmogo.2025.100180

N/A

0DataRank · unranked

0 citations

Van K. Morris, Sheela Rao, Panagiotis Ntellas

NRG-GI005 (COBRA): Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.4_suppl.tps261

N/A

0DataRank · unranked

17 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +7 more

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps4121

N/A

0DataRank · unranked

4 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +7 more

Consensus molecular subtypes (CMS) as a marker for treatment and disease biology in metastatic colorectal cancer (CRC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.4089

N/A

0DataRank · unranked

2 citations

Preeti Kanikarla Marie, Amir Mehrvarz Sarshekeh, Van K. Morris, Dzifa Y. Duose, Baili Zhang +6 more

Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin

UNC Libraries(2020)10.17615/kke1-de47

N/A

0DataRank · unranked

0 citations

Thomas LaFramboise, Michael S. Lee, Cathy Eng, David R. Fogelman, Stanley R. Hamilton +14 more

Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer

UNC Libraries(2020)10.17615/cgjy-ks12

N/A

0DataRank · unranked

0 citations

Michael S. Lee, Stanley R. Hamilton, Zhi-Qin Jiang, Jeffrey S. Morris, Scott Kopetz +7 more

Van K. Morris

Indexed papers

Top data-sharing exemplar

Papers